Drugs / M923
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02675023 | Jan → Jul 2016 | — | Momenta Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02581345 | Sep 2015 → Apr 2017 | psoriasis | Momenta Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02722044 Background | Apr 2016 → Feb 2017 | rheumatoid arthritis | Momenta Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M923 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02581345 ↗ |
| Modality | Monoclonal antibody | “Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)” NCT02675023 ↗ |
| Route | Subcutaneous | “0.8 mL (40 mg) subcutaneous (SC) dose” NCT02675023 ↗ |